/OCGN
OCGN Stock - Ocugen, Inc.
Healthcare|BiotechnologyNASDAQ
$1.40-2.78%
$0.04 (-2.78%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+257.1%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OCGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.39 – $1.41
TARGET (TP)$5.00
STOP LOSS$1.29
RISK/REWARD1:32.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.54
52W High$1.90
52W Low$0.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.05M | $6.04M | $2.49M | N/A | $43,000 |
| Gross Profit | $2.09M | $5.33M | $2.49M | N/A | $-6,311,000 |
| Gross Margin | 51.5% | 88.3% | 100.0% | N/A | -14676.7% |
| Operating Income | $-54,757,000 | $-65,531,000 | $-89,071,000 | $-58,028,000 | $-21,285,000 |
| Net Income | $-54,054,000 | $-63,078,000 | $-86,804,000 | $-58,365,000 | $-21,822,000 |
| Net Margin | -1333.0% | -1045.0% | -3488.9% | N/A | -50748.8% |
| EPS | $-0.20 | $-0.26 | $-0.40 | $-0.30 | $-0.31 |
Company Overview
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 257.1% Upside
Now
$4
Low
$5
Average
$8
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 15th 2024 | Maxim Group | Initiation | Buy | $4 |
| March 1st 2023 | Chardan Capital Markets | Upgrade | Buy | $3.5 |
| August 23rd 2022 | Mizuho | Initiation | Buy | $5 |
| June 15th 2022 | ROTH Capital | Resumed | Buy | $8 |
| June 2nd 2022 | Cantor Fitzgerald | Initiation | Overweight | $4.5 |
Earnings History & Surprises
OCGNBeat Rate
44%
Last 18 quarters
Avg Surprise
-26.5%
EPS vs Estimate
Beats / Misses
8/6
4 met exactly
Latest EPS
$-0.07
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.03vs$-0.06
Q2 24
+33.3%
$-0.04vs$-0.06
Q3 24
+33.3%
$-0.04vs$-0.06
Q4 24
0.0%
$-0.05vs$-0.05
Q1 25
0.0%
$-0.05vs$-0.05
Q2 25
+16.7%
$-0.05vs$-0.06
Q3 25
+16.7%
$-0.05vs$-0.06
Q4 25
-21.7%
$-0.07vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.06 | $-0.07 | -21.7% | ✗ MISS |
Q3 2025 | Aug 1, 2025 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2024 | Nov 14, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2024 | Aug 8, 2024 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q3 2023 | Aug 21, 2023 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q2 2023 | May 5, 2023 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.10 | $-0.10 | 0.0% | = MET |
Q3 2022 | Aug 5, 2022 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q2 2022 | May 6, 2022 | $0.05 | $-0.09 | -280.0% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.03 | $-0.13 | -333.3% | ✗ MISS |
Latest News
Ocugen Q3 Sales $1.752M Beat $550.000K Estimate
📈 PositiveBenzinga•Nov 5, 2025, 11:33 AM
On Sept 16, Carisma Terminates Merger Agreement With Ocugen
📉 NegativeBenzinga•Sep 18, 2025, 03:14 PM
Ocugen shares are trading higher after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.
📈 PositiveBenzinga•Sep 15, 2025, 03:39 PM
Ocugen Strikes $7.5M Licensing Deal Giving Kwangdong Exclusive Korean Rights To Gene Therapy For Blindness
📈 PositiveBenzinga•Sep 15, 2025, 10:10 AM
Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.
📈 PositiveBenzinga•Sep 2, 2025, 01:08 PM
Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.
📈 PositiveBenzinga•Aug 29, 2025, 08:29 PM
Carisma Therapeutics To Receive $5M Investment From Ocugen As Part of Merger With Ocugen Subsidiary OrthoCellix
📈 PositiveBenzinga•Aug 29, 2025, 08:26 PM
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST
📈 PositiveSeeking Alpha•Jun 16, 2025, 01:38 PM
Ocugen signs license deal with Korean company for gene therapy
📈 PositiveSeeking Alpha•Jun 5, 2025, 01:32 PM
Frequently Asked Questions about OCGN
What is OCGN's current stock price?
Ocugen, Inc. (OCGN) is currently trading at $1.40 per share. The stock has moved -2.78% today.
What is the analyst price target for OCGN?
The average analyst price target for OCGN is $5.00, based on 1 analyst.
What sector is Ocugen, Inc. in?
Ocugen, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OCGN's market cap?
Ocugen, Inc. has a market capitalization of $0.44 billion, making it a small-cap company.
Does OCGN pay dividends?
No, Ocugen, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
ALMS
Alumis Inc. Common Stock
$11.29
Mkt Cap: $1.2B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
LCTX
Lineage Cell Therapeutics, Inc.
$1.68
Mkt Cap: $0.4B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
NGNE
Neurogene Inc.
$20.55
Mkt Cap: $0.3B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to OCGN for comparison